Drug intelligence / Profile preview

LY01612

Development stage: Phase 1
Lead developer: Luye Pharma
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intravenous

Overview

**LY01612** is a pegylated liposomal formulation of **doxorubicin hydrochloride**, a **small molecule** anthracycline **topoisomerase II inhibitor** used as an antineoplastic agent. It encapsulates doxorubicin in liposomes to improve pharmacokinetics, reduce toxicity, and enhance tumor targeting compared to conventional doxorubicin. Developed by **Luye Pharma**, it is being evaluated for **advanced breast cancer** and likely other solid tumors, with bioequivalence demonstrated to **Caelyx** (Doxil) in Chinese patients via studies measuring free and encapsulated doxorubicin concentrations.[3][4][10][15]

Targets

TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on LY01612.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY01612.

Explore the full profile